Shares of BioInvent International AB (STO:publ) last traded at 2.255, representing a move of -0.66%, or -0.015 per share, on volume of 231,298 shares. After opening the trading day at 2.285, shares of BioInvent International AB traded in a close range. BioInvent International AB currently has a total float of 350.80 million shares and on average sees 622,395 shares exchange hands each day. The stock now has a 52-week low of 1.8 and high of 2.96.

Nasdaq Stockholm: A Nordic Nation’s Pride

Sweden is home to one of the best and most accomplished economies in the world. It is truly a pride of the European Union (EU), especially now that Great Britain has decided to leave the political organization. BioInvent International AB is not very concern for its investors. With the Brexit, the Swedish economy is now more than ever at a more competent position to carry out growth prospects.

Stockholm Stock Exchange or Nasdaq Stockholm

The Nasdaq Stockholm, located in Frihamnen, Stockholm, is the primary stock exchange in Sweden. It is also one of the main stock exchanges in other Nordic countries including Denmark, Finland, Iceland, and Norway.

The Nasdaq Stockholm had been established as early as 1863, making it one of the oldest stock exchange in Europe and in the world as well. Until about the first half of the calendar year 1990, trading on the Nasdaq Stockholm occurs on the floor at the Stockholm Stock Exchange Building. Electronic trading was only launched on June 1, 1990. And now it provides numerous improvements in the common work for BioInvent International AB.

Nasdaq, Inc. owns the Nasdaq Stockholm since 2008. Consequently, it is part of Nasdaq Nordic, a subsidiary of Nasdaq founded in 2003. Other stock exchanges overseen by Nasdaq Nordic include the Armenia Stock Exchange or Nasdaq OMX Armenia, the Copenhagen Stock Exchange or Nasdaq Copenhagen, the Helsinki Stock Exchange or Nasdaq Helsinki, the Iceland Stock Exchange or Nasdaq Iceland, the Riga Stock Exchange or Nasdaq Baltic, and the Tallinn Stock Exchange or Nasdaq Baltic.

As of March, more than 300 companies are listed on the Nasdaq Stockholm. In totality, it has a market capitalization of roughly $1.26 trillion.

The regular trading session on the Nasdaq Stockholm begins at 9:00 a.m. and ends at 5:00 p.m.

OMX Stockholm 30 Index (OMXS30)

The OMXS30 is the benchmark Swedish index measuring the top 30 stocks on the Nasdaq Stockholm based on market capitalization. It uses the base value of 125 points, which has a base date of September 1986. The OMXS30 has numerous sectors; and the three biggest sectors include Consumer Services, Financials, and Industrials. OMXS30 guarantee the stability for BioInvent International AB work, as well.

The components of the OMXS30 are reviewed semi-annually in order to guarantee an accurate representation of the Swedish equity market. During rebalancing periods, it is only normal for the OMXS30 to forego some components and welcome new ones. It always depends on the companies’ liquidity, market capitalization, and several other factors.

The OMXS30 has touched its all-time low of 98.86 points in November 1987. The substantial losses are widely attributed to the Black Monday, an occurrence that had shaken the global equity market. It all began when stocks on the Stock Exchange of Hong Kong (SEHK) had significantly declined on October 19, 1987.

Eventually, the OMXS30 was able to recoup from the dark times in global economy history. It has touched its all-time high of 1,719.93 in April 2015.

Today is the best time to enter the European equity market, particularly that of Sweden. And perhaps check some companies like BioInvent International AB. With low interest rates, Europe is surely an ideal place for investors to bet on through the Nasdaq Stockholm.

More news for BioInvent International AB (STO:publ) were recently published by: Businesswire.com, which released: “BioInvent Enter Process Development and Manufacturing Collaboration with Alligator – Business Wire” on July 08, 2016. Businesswire.com‘s article titled: “Annual General Meeting in BioInvent International AB – Business Wire” and published on April 12, 2016 is yet another important article.

BioInvent International AB , a research pharmaceutical company, focuses on the discovery and development of antibody drugs against cancer. The company has market cap of $791.05 million. The company's lead drug candidate is BI-1206, a human antibody targeting CD32b, an immunosuppressive protein that is expressed in patients with B-cell cancers. It currently has negative earnings. The BI-1206 drug is in Phase I/II clinical trials currently ongoing in patients with non-Hodgkin lymphoma and chronic lymphocytic leukaemia who are resistant to rituximab.